CA-NETAPP
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Spot by NetApp has achieved the FinOps Certified Platform certification from the FinOps Foundation, validating the platform's ability to provide the depth and breadth of capabilities organizations need to practice sound cloud financial management. Also, Spot by NetApp has expanded its certified platform with the general availability of its Cost Intelligence and Billing Engine solutions.
As organizations move increasing amounts of their workloads to the cloud, especially to fuel the development of AI applications, balancing the competing needs of infrastructure and financial efficiency becomes more difficult. Overprovisioning cloud resources results in wasted expenses, but under-provisioning can slow business operations and stifle innovation. The traditional approach of standalone FinOps tools, with their focus on cost cutting, fall short of meeting these evolved requirements to deliver cost-effective yet high-performance cloud infrastructure.
Spot by NetApp closes this technology gap by delivering a holistic, integrated portfolio of FinOps solutions that supports an organization’s intelligent data infrastructure. With its breadth of capabilities, organizations can unify cloud cost and infrastructure optimization, deliver analytics to maximize the efficiency and impact of every dollar spent in the cloud, and drive digital business growth. Becoming a FinOps Certified Platform helps Spot by NetApp enable its customers to successfully adopt cloud best practices aligned with the FinOps standards.
“According to the FinOps Framework, implementing a productive FinOps strategy requires effective collaboration between teams. Effective collaboration requires full access to both financial and cloud operations data,” said Mike Fuller, CTO of the FinOps Foundation. “A thoughtful and comprehensive approach to FinOps helps organizations maximize the business value of the cloud so they can more easily achieve their business goals. We recognize Spot by NetApp as a FinOps Certified Platform due to its ability to deliver software that helps organizations successfully adopt FinOps practices.”
To support this comprehensive approach to FinOps, Spot by NetApp has integrated the cloud cost management capabilities of Cloudcheckr into its portfolio with the introduction of two new product modules:
- Cost Intelligence: This product delivers panoramic visibility with actionable insights on cloud costs, resources, and usage across multi-cloud environments through interactive dashboards and drill down reports. To support the cost optimization process, Cost Intelligence provides best practice checks that immediately flag problems and help users optimize spend, effectively utilize resources, reduce waste, and address misconfigurations.
- Billing Engine: This product provides comprehensive billing reporting with intelligent cost allocation capabilities including chargeback and showback. With this product, businesses can better track and manage cloud spend across different groups to drive accountability.
FinOps teams will benefit from a single source of truth for financial and cloud operations data. The release of Cost Intelligence and Billing Engine improves the effectiveness of all solutions in the Spot by NetApp portfolio. For example, organizations will be able to use Spot Ocean and Elastigroup’s machine learning and AI analytics together with Cost Intelligence’s advanced cost analysis to deliver the most accurate optimization recommendations. Teams can further simplify their FinOps practices by automatically applying those recommendations to their infrastructure.
"The expansion of our integrated FinOps offering and becoming a FinOps Certified Platform is a true validation of Spot by NetApp's vision and approach to leveraging data and technology to help customers get the most from their cloud investments,” said Haiyan Song, Executive Vice President of Cloud Operations at NetApp. “Our comprehensive and integrated portfolio spans financial management and continuous cloud infrastructure optimization. We continue to innovate and evolve our cutting-edge AI powered solutions, harnessing the intelligence from the vast workloads and infrastructure under management by Spot by NetApp to provide critical insights in FinOps management and enable autoscaling and continuous optimization. Expanding our FinOps offerings with Cost Intelligence and Billing Engine is another step forward in our ongoing mission to support our customers and unlock more value from the cloud.”
"Utilizing Spot by NetApp's tools through RealCloud has been a game-changer for our FinOps operations,” said Luis Martinez, Cloud and Network Infrastructure Manager at Genial Investimentos. “Through intelligent automation and advanced visibility provided by these solutions, we have significantly optimized our cloud costs while increasing operational efficiency. Our partnership with Spot by NetApp and RealCloud has enabled us not only to reduce expenses but also to reinvest those savings into innovation and strategic growth for the company."
To learn more about the Spot by NetApp solution for FinOps, visit the Spot by NetApp booth #G3 at the FinOps X conference running from June 19-22 at The Marriott Marquis, San Diego
Additional Resources
- Helping Companies Go Beyond Savings with Spot by NetApp for FinOps
- Cost Intelligence: Reduce costs through actionable insights on your cloud environment, all in one place
- Billing Engine: Streamline invoicing with a flexible, customizable billing engine
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620996726/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
